Huntington's Disease Clinical Trial
Official title:
The Effect of Video Game Biofeedback Modulated Exercise (ViBE)on Dynamic Balance and Gait in Individuals With Huntington's Disease
NCT number | NCT01735981 |
Other study ID # | 2008H0109 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2008 |
Est. completion date | June 2012 |
Verified date | July 2021 |
Source | Ohio State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To examine the benefits of using a video-game, Dance, Dance, Revolution, as an exercise modality to improve gait and balance in individuals with Huntington's disease.
Status | Completed |
Enrollment | 24 |
Est. completion date | June 2012 |
Est. primary completion date | November 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 79 Years |
Eligibility | Inclusion Criteria: - adults 18 - 79 with a diagnosis of Huntington's disease Exclusion Criteria: - cannot walk 10 feet without assistance, any other neurologic condition |
Country | Name | City | State |
---|---|---|---|
United States | The Ohio State University Atwell Hall | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Anne Kloos |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Gait Parameters | utilized GAITRite to obtain spatiotemporal measures of gait: forward velocity. | 6 weeks | |
Primary | Gait Parameters | utilized GAITRite to obtain spatiotemporal measures of gait: forward stride length. | 6 weeks | |
Primary | Gait Parameters | utilized GAITRite to obtain spatiotemporal measures of gait: forward swing percent. | 6 weeks | |
Primary | Gait Parameters | utilized GAITRite to obtain spatiotemporal measures of gait: forward double support percent. | 6 weeks | |
Primary | Gait Parameters | utilized GAITRite to obtain spatiotemporal measures of gait: forward heel to heel base of support. | 6 weeks | |
Primary | Gait Parameters | utilized GAITRite to obtain spatiotemporal measures of gait: backwards velocity. | 6 weeks | |
Primary | Gait Parameters | utilized GAITRite to obtain spatiotemporal measures of gait: backwards stride length. | 6 weeks | |
Primary | Gait Parameters | utilized GAITRite to obtain spatiotemporal measures of gait: backwards swing percent. | 6 weeks | |
Primary | Gait Parameters | utilized GAITRite to obtain spatiotemporal measures of gait: backwards double support percent. | 6 weeks | |
Primary | Gait Parameters | utilized GAITRite to obtain spatiotemporal measures of gait: backwards heel to heel base of support. | 6 weeks | |
Primary | Gait Parameters | utilized GAITRite to obtain spatiotemporal measures of gait: obstacle velocity. | 6 weeks | |
Secondary | Tinetti Mobility Test | Observation of gait and balance with quantifiable 16-item assessment with an ordinal scale of 0-2 for up to a total score of 32, with higher scores indicating better performance. It is reliable and predicts falls among those with Parkinson's disease and Huntington's disease. | 6 weeks | |
Secondary | Four Square Step Test | Examines ability to step over an object in multiple directions and is timed. Participants are instructed to step over a cane into each square in a specific order. Faster times indicate better balance. It has been shown to predict falls in the elderly. | 6 weeks | |
Secondary | Activities-Specific Balance Confidence Scale | Individuals rate their balance confidence from 1-100 on 16 tasks and total score is the mean; higher scores indicate greater confidence and lower fall risk. The Activities-Specific Balance Confidence Scale is reliable and valid in elderly and neurological populations. | 6 weeks | |
Secondary | World Health Organization Quality of Life | This questionnaire is a measure of quality of life addressing 4 domains including physical, psychological, social, and environment health. Responses on 26 items are on a five-point scale (from 1 = very dissatisfied to 5 = very satisfied) and each item is added to achieve a total score for each domain. The mean score for each domain is calculated then multiplied by 4 to get the domain score which are then transformed to a scaled score of 0-100 comparable to the original WHOQOL-100 therefore a total score between 0-400 with high scores indicating better quality of life. The WHOQOLBref has good reliability and validity. | post intervention and post hand-held game, each lasts 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04120493 -
Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02956148 -
Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers
|
Early Phase 1 | |
Terminated |
NCT02494778 -
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
|
Phase 2 | |
Completed |
NCT02208934 -
Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers
|
Phase 1 | |
Completed |
NCT02216474 -
Brain Stimulation in Movement Disorders
|
N/A | |
Completed |
NCT02197130 -
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
|
Phase 2 | |
Completed |
NCT01806896 -
Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease
|
Phase 2 | |
Completed |
NCT01502046 -
Neuroprotection by Cannabinoids in Huntington's Disease
|
Phase 2 | |
Terminated |
NCT00712426 -
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)
|
Phase 3 | |
Completed |
NCT00670709 -
Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease
|
||
Completed |
NCT00029874 -
Minocycline in Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT02231580 -
Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients
|
Phase 2 | |
Completed |
NCT02215616 -
A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod
|
Phase 2 | |
Not yet recruiting |
NCT02551705 -
Functional Imaging of Social Cognition in Premanifest Huntington's Disease
|
N/A | |
Active, not recruiting |
NCT02101957 -
Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)
|
Phase 2/Phase 3 | |
Completed |
NCT00975481 -
A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
|
Phase 1 | |
Completed |
NCT00990613 -
A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin
|
Phase 1 | |
Completed |
NCT01521832 -
Escalating Dose Study in Healthy Volunteers With SEN0014196
|
Phase 1 | |
Completed |
NCT00387270 -
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT00095355 -
Effects of Lithium and Divalproex`on Brain-Derived Neurotrophic Factor in Huntington's Disease
|
Phase 2 |